Hikma outlines growth drivers, consensus picture for the shares
Published on 06/30/2026 at 09:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 09:02.
Hikma Pharmaceuticals (GB00B128J450) enters Tuesday with a defined role in the global generics and specialty pharma segment. The London-listed group sits alongside peers such as Teva and Viatris in supplying off-patent and branded medicines to regulated markets.
What analysts focus on
Coverage of Hikma typically centers on three operating divisions: injectables, generic oral medicines, and branded pharmaceuticals in the Middle East and North Africa. Analysts track growth in each segment against demand for hospital injectables and chronic-disease therapies.
Consensus models usually incorporate mid-single to low-double-digit revenue growth for injectables, reflecting ongoing demand for sterile hospital products and occasional product launches. For generics, assumptions often factor in pricing pressure but also volume growth from portfolio breadth.
Tuesday’s consensus angle
On a Tuesday consensus day, investors examine rating distribution, target-price ranges, and earnings expectations for Hikma. The stock is commonly followed by international houses and regional brokers that compare the company’s metrics with global generics and specialty pharma peers.
Rating spreads for Hikma historically cluster around neutral to positive, with target prices reflecting views on sustainable margins, product mix, and exposure to emerging markets. Earnings expectations factor in currency movements, input costs, and regulatory dynamics in core markets.
Background and price data on Hikma
Further news, price data and regulatory disclosures help investors place Hikma’s shares in the wider generics and specialty pharma landscape.
How Hikma makes money
Hikma generates revenue primarily through its injectables portfolio, which includes antibiotics, oncology agents and other hospital products supplied to markets such as the US and Europe. Additional income comes from generic oral medicines and branded therapies in the Middle East and North Africa.
Where the stock trades today
The Hikma shares (GB00B128J450) are listed in London, with trading and price formation centered on the London Stock Exchange in pounds sterling as of 2026-06-30, 09:02.
Key data on the Hikma shares
- Company: Hikma Pharmaceuticals PLC
- ISIN: GB00B128J450
- WKN: not available
- Ticker: HIK
- Trading venue: London Stock Exchange
- Price (as of 2026-06-30, 09:02): not live-verified GBP
- Market cap: not live-verified GBP (as of 2026-06-30)
- Sector / industry: Pharmaceuticals, generics and specialty medicines
- Index membership: FTSE index family association
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. All data as of the stated date; figures may change over time.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
